Conference
CREATe Therapeutics Showcases Drug-Controlled Gene Therapy Platform at CGTI EU

It was great to speak at CGTI EU in Berlin about CREATe Therapeutics' work on drug-controlled CNS gene therapy—a platform we’re developing to address a range of neurological disorders, with drug-resistant focal epilepsy as our lead indication

.It was energizing to share our approach and exchange ideas with so many colleagues pushing the boundaries of what’s possible in CNS therapeutics. The discussions and feedback were invaluable, and I’m grateful to the CGTI community for the engagement.

Excited to continue advancing this work with the team at CREATe Therapeutics.

Latest
News
The latest industry news, interviews, technologies, and resources.
View All News
Latest
News
The latest industry news, interviews, technologies, and resources.
Kv1.3
May 12, 2026
By VRG Therapeutics
Press Release
Kv1.3
April 13, 2026
By VRG Therapeutics
VRG Miniprotein Secures €4M Catalyst Grant to Advance Kv1.3 Program
View All News